Comparison of enhanced elimination of bismuth in humans after treatment with meso-2,3-dimercaptosuccinic acid and D,L-2,3-dimercaptopropane-1-sulfonic acid.
Two groups of 12 human volunteers, who had been treated with colloidal bismuth subcitrate, because of Helicobacter pylori-associated gastritis, participated in the study. The patients received a single dose of meso-2,3-dimercaptosuccinic acid (DMSA) or D,L-2,3-dimercaptopropane-1-sulfonic acid (DMPS) at a dose of 30 mg kg-1 in a randomized single blind study. In contrast to DMPS, increasing concentrations of bismuth in blood were observed during the first 4 h after intake of DMSA. In urine, both chelators induced a 50-fold increase in urinary bismuth excretion compared with the control urines. The treatment was well tolerated. The results indicate that both DMSA and DMPS effectively increase the elimination of bismuth in human urine. Consequently, both chelators may be of benefit in the treatment of patients with bismuth intoxication.
Slikkerveer
A
A
Toxicology Laboratory, Leiden University Medical Centre, The Netherlands.
Noach
L A
LA
Tytgat
G N
GN
Van der Voet
G B
GB
De Wolff
F A
FA
D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D000863:Antacids / Q000627:therapeutic use*; D001729:Bismuth / Q000097:blood / Q000378:metabolism* / Q000652:urine; D002614:Chelating Agents / Q000627:therapeutic use*; D005756:Gastritis / Q000188:drug therapy / Q000378:metabolism / Q000382:microbiology; D016481:Helicobacter Infections / Q000188:drug therapy / Q000378:metabolism; D006801:Humans; D008875:Middle Aged; D009942:Organometallic Compounds / Q000627:therapeutic use*; D016037:Single-Blind Method; D004113:Succimer / Q000627:therapeutic use*; D014494:Unithiol / Q000627:therapeutic use
D000863:Antacids; D002614:Chelating Agents; D009942:Organometallic Compounds; D014494:Unithiol; D004113:Succimer; C002791:bismuth tripotassium dicitrate; D001729:Bismuth